VP1-2022: Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer

Andrew Tutt, John J. Garber, R.D. Gelber, Kelly‐Anne Phillips, Andrea Eisen, Oskar T. Johannsson, Priya Rastogi, Karen Cui, S-A. Im, R. Yerushalmi, Adam Brufsky, Maria Taboada, Giovanna Rossi, Greg Yothers, C Singer, Luis Fein, Niklas Loman, David Cameron, Christine Campbell, CE Geyer